Patents by Inventor MATTHEW ROTZ

MATTHEW ROTZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY
    Publication number: 20220135529
    Abstract: Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific T1-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific T1 contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
    Type: Application
    Filed: January 13, 2022
    Publication date: May 5, 2022
    Inventors: Sangeeta Ray, Martin G. Pomper, Thomas J. Meade, Ronnie C. Mease, Ying Chen, Xing Yang, Matthew Rotz
  • METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY
    Publication number: 20200290982
    Abstract: Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific T1-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific T1 contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
    Type: Application
    Filed: May 29, 2020
    Publication date: September 17, 2020
    Inventors: Sangeeta Ray, Martin G. Pomper, Thomas J. Meade, Ronnie C. Mease, Ying Chen, Xing Yang, Matthew Rotz
  • Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy
    Patent number: 10683272
    Abstract: Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: June 16, 2020
    Assignees: THE JOHNS HOPKINS UNIVERSITY, NORTHWESTERN UNIVERSITY
    Inventors: Sangeeta Ray, Martin G. Pomper, Thomas J. Meade, Ronnie C. Mease, Ying Chen, Xing Yang, Matthew Rotz
  • METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY
    Publication number: 20170081298
    Abstract: Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
    Type: Application
    Filed: May 6, 2015
    Publication date: March 23, 2017
    Applicants: THE JOHNS HOPKINS UNIVERSITY, NORTHWESTERN UNIVERSITY
    Inventors: SANGEETA RAY, MARTIN G. POMPER, THOMAS J. MEADE, RONNIE C. MEASE, YING CHEN, XING YANG, MATTHEW ROTZ